See the DrugPatentWatch profile for qulipta
Qulipta (atogepant) was approved by the U.S. Food and Drug Administration (FDA) in September 2021 [1]. This means it has been available on the market for approximately two years and seven months as of May 2024.
When does Qulipta's patent protection end?
The primary patent covering Qulipta, U.S. Patent No. 10,500,401, is scheduled to expire in June 2037 [1][2]. However, patent expiry timelines can be complex and are subject to various factors, including potential patent challenges and the granting of additional patents [3].
Can generic versions of Qulipta be made before its patent expires?
Generally, generic versions of a drug cannot be marketed before the expiration of its primary patents and any granted exclusivities. The development and approval process for generic drugs, including biosimilars for biologic drugs, requires demonstrating bioequivalence or similarity to the reference product. Any potential generic or biosimilar entry before the patent expiry would likely involve patent litigation or other legal challenges [3].
Who makes Qulipta?
Qulipta is manufactured by AbbVie Inc. [1]. AbbVie acquired Allergan, the original developer of Qulipta, in 2020 [4].
What is Qulipta used for?
Qulipta is a medication used for the preventive treatment of episodic migraine in adults [1]. It belongs to a class of drugs known as calcitonin gene-related peptide (CGRP) receptor antagonists.
How does Qulipta work?
Qulipta works by blocking the action of CGRP, a molecule that is believed to play a role in migraine headaches [1]. By inhibiting CGRP, Qulipta helps to prevent migraine attacks from occurring.
What are the side effects of Qulipta?
Common side effects reported with Qulipta include upper respiratory infection, nausea, and fatigue [1]. Patients experiencing any adverse reactions should consult with their healthcare provider.
How does Qulipta compare to other migraine preventatives?
Qulipta is one of several CGRP-targeted therapies available for migraine prevention. Other medications in this class include oral gepants like Ubrelvy (ubrogepant) and Nurtec ODT (rimegepant), as well as injectable monoclonal antibodies such as Aimovig (erenumab), Ajovy (fremanezumab), Emgality (galcanezumab), and Vyepti (eptinezumab) [5][6]. The choice of medication often depends on individual patient needs, response, and tolerability.
What is the cost of Qulipta?
The cost of Qulipta can vary depending on insurance coverage and pharmacy. AbbVie offers patient assistance programs that may help eligible individuals reduce their out-of-pocket costs [7].
Sources:
[1] https://www.drugpatentwatch.com/drugs/qulipta
[2] https://www.drugpatentwatch.com/patents/qulipta
[3] https://www.drugpatentwatch.com/
[4] https://www.abbvie.com/news-and-updates/press-releases/abbvie-completes-acquisition-of-allergan.html
[5] https://www.drugpatentwatch.com/blog/understanding-the-market-for-migraine-treatment-drugs
[6] https://www.drugpatentwatch.com/browse/drug-class/cgrp-antagonists
[7] https://www.qulipta.com/patient-support